Leading-edge medical care through clinical research.

Getting care at AdventHealth Tampa, formerly Florida Hospital Tampa, means getting access to the latest heart care research studies, procedures, and technologies including access to heart treatment clinical trials that aren’t widely available elsewhere.

Following is a list of active studies in which we are currently enrolling patients. If you would like more information about a trial, please call Call813-615-7527 or visit clinicaltrials.gov.

Active Research Trials

CARDIOVASCULAR TRIALS

AEGIS II: InvestigatingCSL112 in Subjects with Acute Coronary Syndrome. Lead: Poliana Desarden


AKI: The purpose of this study is to evaluate the efficacy of post-surgery treatment with ASP1128 in subjects at risk for acute kidney injury (AKI) following CABG and/or valve surgery Lead: Mari Hardy


APPRAISE ATP: Assessment of primary prevention patients receiving an ICD. Lead: Poliana Desarden


BMAD-HF: Benefits of µCor in ambulatory decompensated heart failure. Lead: Juliet Bala


BIOFLOW-VII: Confirming that the clinical performance of the Orsiro stent in a real-world setting is similar to the clinical performance observed for Orsiro in the BIOFLOW-V Investigational Device Exemption pivotal trial. LeadJuliet Bala


BIO-LIBRA: Analysis of sex and device specific factors on outcomes in patients with non-ischemic cardiomyopathy. LeadJuliet Bala


CADFEM: Phase signal acquisition system (PSAQ), a medical device system. Lead: Mari Hardy


CONNECT-HF: Optimization through patient and hospital engagement clinical trial for heart failure. Lead: Melanie Stinson


CLOUT: Evaluate real world patient outcomes after treatment of acute and non-acute lower extremity deep vein thrombosis (DVT) with the ClotTriever Thrombectomy System.Lead: Juliet Bala


FROZEN: To establish the safety and effectiveness of the Boston Scientific Cardiac Cryoablation System for treatment of symptomatic, drug refractory, recurrent, paroxysmal atrial fibrillation. Lead: Cynthia Paysor


KNOCOUT PE: Ekosonic registry of the treatment and clinical outcomes of pulmonary embolism. LeadJuliet Bala


 

NEUROSCIENCE TRIALS

EP0092: To evaluate the efficacy, safety and tolerability of the 3 selected dose regimens of padsevonil (PSL) administered concomitantly with up to 3 anti-epileptic drugs (AEDs) compared with placebo for treatment of observable focal-onset seizures in subjects with drug-resistant epilepsy. Lead: Poliana Desarden


LGS001: Open-label, multi-center study of carisbamate in adult and pediatrics with Lennox-Gastaut Syndrome. Lead: Poliana Desarden


XENON: Randomized trial to evaluate safety, tolerability and efficacy of XEN1101 as adjunctive therapy in focal-onset epilepsy. Lead: Mari Hardy


 

DIGESTIVE HEALTH TRIALS

ABBVIE M14-234:A Study to Evaluate the Safety and Efficacy of Upadacitinib for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis. Lead: Christopher Carr


ABBVIE M14-430: A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib in Subjects with Crohn's Disease. Lead: Christopher Carr


ABBVIE M14-431: A Study of the Efficacy and Safety of Upadacitinib in Subjects with Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy. Lead: Christopher Carr


ABBVIE M14-433: A Study of the Efficacy and Safety of Upadacitinib in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies. Lead: Christopher Carr


ABBVIE M14-533: A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib in Subjects With Ulcerative Colitis. Lead: Christopher Carr


ABBVIE M14-675: A Study of the Efficacy and Safety of Upadacitinib in Participants with Moderately to Severely Active Ulcerative Colitis (U-Accomplish). Lead: Christopher Carr


ABBVIE M16-066: A Study to Assess the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis Who Responded to Induction Treatment in M16-067 or M16-065. Lead: Christopher Carr


ABBVIE M16-067: A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants with Moderately to Severely Active Ulcerative Colitis (U-Accomplish). Lead: Christopher Carr


ADMIRE-CD-II: Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Patients with Crohn's Disease. Lead: Christopher Carr


AURORA: Phase 3 study to evaluate cenicriviroc for treatment of liver fibrosis in patients with NASH.Lead: Christopher Carr


EPIDURAL vs GENERAL: Comparing Epidural Versus General Anesthesia for LESS Cholecystectomies. Lead: Trenton Lippert


GALAXI: A Study of the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease. Lead: Christopher Carr


GHPANC-1-001: Determine Function of Antroquinonol in Combination with SOC in First Line Metastatic Pancreatic Cancer. Lead: Christopher Carr


HBOT: Randomized 1:1 pre-operative hyperbaric oxygen therapy (HBOT) vs. no therapy to determine if pre-op HBOT can improve post-operative outcomes. Lead: Trenton Lippert


PANC VOL: Study to determine if length of duodenum and volume of pancreas removed can be used as a predictive factor for the development of post-operative diabetes. Lead: Trenton Lippert


PANOVA-3: Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant with Gemcitabine and Nab-paclitaxel. Lead: Trenton Lippert


TAMLAPS: Registry and tissue sample consent specifically for patients scheduled for the TAMLAPS procedure.Lead: Trenton Lippert


TYME-88: A Multi-Center Study of SM-88 in Subjects with Pancreatic Cancer. Lead: Christopher Carr


 

RHEUMATOLOGY TRIALS

AMG-570/SLE: Determine if AMG 570 could be a useful therapeutic agent in the current treatment landscape where subjects with systemic lupus erythematosus (SLE) have ongoing disease activity despite treatment with standard of care therapies. Lead: Courtney Humiston


B7931028: Assessment of PF-06700841 in participants with moderate to severe active, generalized Systemic Lupus Erythematosus (SLE) that have inadequate response to standard of care. Lead: Dianne Morales


BMS-IM1121/SLE: An Investigational Study to Evaluate BMS-986165 in Patients with Systemic Lupus Erythematosus. Lead: Gretchen Pifer


GSK-20190: Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate. Lead: Judy Lara


GSK-20218: Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors. Lead: Judy Lara


KZR 606-202/INC/SLE: A Study of KZR-616 in Patients with Systemic Lupus Erythematosus with and without Nephritis.Lead: Gretchen Pifer


 

PA0010: A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis (BE OPTIMAL). Lead: Marisabel Collado


PA0011: A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects with Active Psoriatic Arthritis (BE COMPLETE). Lead: Marisabel Collado


TV48125: A Study to Test the Effectiveness and Safety of Fremanezumab on Patients With Fibromyalgia. Lead: Nyasha McLean